My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC - Episode 8

Considerations for First-Line Targeted Therapies in Metastatic RET-Positive NSCLC

,

Panelists discuss the specific factors that influence the decision to initiate one of the NCCN guideline–preferred RET inhibitors, selpercatinib or pralsetinib, over the other in the treatment of RET fusion–positive NSCLC.

EP. 1: Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing
EP. 2: Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy
EP. 3: Testing Methodologies and Standards in Metastatic NSCLC
EP. 4: Practical Considerations in Metastatic NSCLC: Access and Timing of Testing
EP. 5: Clinical-Decision Making: When to Treat Advanced NSCLC Without Mutational Results
EP. 6: Initial Approach to Management of RET-Positive NSCLC
EP. 7: Patient and Therapy Considerations Guiding Initiation of Treatment in RET-Positive NSCLC
Now Viewing
EP. 8: Considerations for First-Line Targeted Therapies in Metastatic RET-Positive NSCLC
EP. 9: Role of Immunotherapy and Chemotherapy in RET-Positive NSCLC
EP. 10: Managing RET Inhibitor Treatment-Related Adverse Events
  • Dr Wakelee to Dr Sands: What specific factors aid in your decision to initiate one of the NCCN guideline–preferred RET inhibitors (selpercatinib and pralsetinib) over the other?

Related Content:

My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC Video SeriesInsights
Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL
Managing RET Inhibitor Treatment-Related Adverse Events
Role of Immunotherapy and Chemotherapy in RET-Positive NSCLC